Company Metrics

• 0 P/E
• 4803.83 P/S
• 8.91 P/B
• -1.097 EPS
• 226.23% Cash ROIC
• 2.62 Cash Ratio
• 0 / 0% Dividend
• 485,231.00 Avg. Vol.
• 47.20M Shares
• 522.6M Market Cap.

Company Description

Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Its research and development programs include STA-9090, an Hsp90 inhibitor that is in Phase II stage for non-small cell lung cancer and gastrointestinal stromal tumors, as well as in Phase I for hematologic cancers and solid tumors; Elesclomol, an oxidative stress inducer that is in Phase I/II stage for solid and hematologic cancers; and STA-9584, a vascular disrupting agent, which is in preclinical development for cancer. The company's programs also include Apilimod (STA-5326), an oral IL-12/23 inhibitor, which is in Phase IIa stage for rheumatoid arthritis; and Oral CRACMchannelinhibitor that is in preclinical development for autoimmune diseases and respiratory conditions. It has a partnership with Hoffmann-La Roche for the development of CRACM inhibitors; and a joint collaboration with The Multiple Myeloma Research Foundation Inc. for the clinical development of ganetespib in patients with multiple myeloma. The company was incorporated in 2000 and is based in Lexington, Massachusetts.
less

Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Its research and development programs include STA-9090, an Hsp90 inhibitor that is in Phase II stage for non-small cell lung cancer and g...
more

News